[Sacubitril / Valsartan in patients with diabetes and heart failure].
Sacubitril / Valsartan proofed to be an effective treatment compared to enalapril in reducing heart failure hospitalisations and mortality in patients with severe "Heart failure with reduced ejection fraction" (HFREF). Recent European cardiology guidelines attributed a class IB recommendation for Sacubitril / Valsartan in HFREF patients who remain symptomatic despite optimal treatment with ACE-I, a beta-blocker, and a mineralocorticoid receptor antagonist. There is a significant overlap between diabetic and HFREF patients and thus, efficacy assessment of Sacubitril / Valsartan is a clinically meaningful issue in the large subgroup of HFREF patients with diabetes. We discuss the present evidence why local authorities speculated about a potential interaction between the two diseases decreasing the efficacy of sacubitril/valsartan in terms of reducing relevant end-points in this cohort. Overall, Sacubitril / Valsartan is obviously a treatment option in diabetics with HFREF. However, diabetic cardiomyopathy needs to be recognised as a specific disease condition.
Vincent Matthias
VM
Brandenburg
Hans-Peter Brunner-La
HB
Rocca
Nikolaus
N
Marx
D000613:Aminobutyrates / Q000008:administration & dosage*; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001713:Biphenyl Compounds; D048909:Diabetes Complications / Q000150:complications* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000150:complications* / Q000178:diet therapy*; D006801:Humans; D013777:Tetrazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D000068756:Valsartan / Q000008:administration & dosage*
D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; C549068:sacubitril and valsartan sodium hydrate drug combination